Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2025-04-05
2045-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Since the prevalence of the mutation is estimated to be 1:400 - 1:500 individuals, the total number of BRCA mutation carriers should be around 140.000 - 150.000 in the Italian population. It is estimated that 87% of women with BRCA mutations will experience, in their lifetime, a tumor with a genetic origin. About 20% of the 5200 ovarian cancer cases diagnosed each year in Italy has a genetic origin and could potentially be the object of primary prevention. To date, and to the best of our knowledge, a national prospective data collection on women with BRCA mutations has not been yet established.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
NCT00897455
BRCA and NACT in TNBC Patients
NCT05750719
InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2
NCT05835739
BRCA Mutations in Latinas
NCT01251900
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation
NCT03667417
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Registration of clinical datas in the platform
Registration of clinical datas in the platform of female individual carrying a BRCA1 or BRCA2 mutation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All women who known to be carriers of a pathogenetic mutation class 4 and 5 of the International Agency of Research on Cancer classification) of the BRCA1 or BRCA2 genes.
Exclusion Criteria
* No pathogenetic mutation carriers.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Fagotti
Role: PRINCIPAL_INVESTIGATOR
Fondazione Policlinico Universitario A. Gemelli, IRCCS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Malzoni Research Hospital
Avellino, , Italy
Centro di Riferimento Oncologico IRCCS
Aviano, , Italy
Università degli Studi di Bari "Aldo Moro"
Bari, , Italy
IRCCS Istituto Tumori "Giovanni Paolo II"
Bari, , Italy
ASST Papa Giovanni XXIII
Bergamo, , Italy
L'Azienda ospedaliera per l'emergenza "Cannizzaro"
Catania, , Italy
Azienda Ospedaliero Santa Croce e Carle
Cuneo, , Italy
Presidio Ospedaliero Umberto I - ASP di Enna
Enna, , Italy
Azienda Ospedaliero Universitaria Careggi, Oncologia Medica Ginecologica
Florence, , Italy
IRCCS Ospedale Policlinico San Martino
Genova, , Italy
Ospedale S. Maria Goretti, Latina
Latina, , Italy
Ospedale del Tigullio Polo di Lavagna - ASL 4 Chiavarese
Lavagna, , Italy
Ospedale Vito Fazzi, Lecce
Lecce, , Italy
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Meldola, , Italy
IRCCS Ospedale San Raffaele
Milan, , Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, , Italy
Humanitas San Pio X - Milano
Milan, , Italy
Presidio Ospedaliero di Mirano
Mirano, , Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, , Italy
Istituto Nazionale Tumori Fondazione G. Pascale
Napoli, , Italy
Ospedale Mater Olbia
Olbia, , Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, , Italy
Azienda Ospedaliera Universitaria di Parma
Parma, , Italy
Azienda Ospedaliero-Universitaria di Parma
Parma, , Italy
Centro Nazionale di Adroterapia Oncologica
Pavia, , Italy
Fondazione I.R.C.C.S. Policlinico San Matteo
Pavia, , Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, , Italy
Istituto Nazionale Tumori Regina Elena
Roma, , Italy
Istituto Nazionale Tumori Regina Elena
Roma, , Italy
Policlinico Umberto I Università "La Sapienza"
Roma, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Ginecologia Oncologica
Rome, , Italy
Azienda Ospedaliera Universitaria Senese
Siena, , Italy
Ospedale G. Mazzini di Teramo
Teramo, , Italy
Azienda sanitaria universitaria Friuli Centrale
Tolmezzo, , Italy
Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino
Torino, , Italy
Ospedale Mauriziano Umberto I
Torino, , Italy
Azienda ULSS 2 MARCA TREVIGIANA
Treviso, , Italy
IRCCS materno infantile Burlo Garofolo
Trieste, , Italy
Azienda Ospedaliera Universitaria Integrata
Verona, , Italy
AULSS 8 Berica
Vicenza, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4224
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.